0001140361-24-025256.txt : 20240510 0001140361-24-025256.hdr.sgml : 20240510 20240509193846 ACCESSION NUMBER: 0001140361-24-025256 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240509 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240510 DATE AS OF CHANGE: 20240509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PDS Biotechnology Corp CENTRAL INDEX KEY: 0001472091 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 264231384 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37568 FILM NUMBER: 24932488 BUSINESS ADDRESS: STREET 1: 303A COLLEGE ROAD EAST CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: 800-208-3343 MAIL ADDRESS: STREET 1: 303A COLLEGE ROAD EAST CITY: PRINCETON STATE: NJ ZIP: 08540 FORMER COMPANY: FORMER CONFORMED NAME: Edge Therapeutics, Inc. DATE OF NAME CHANGE: 20090911 8-K 1 ef20028859_8k.htm 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 9, 2024

 
PDS BIOTECHNOLOGY CORPORATION
(Exact Name of Registrant as Specified in Charter)

Delaware
001-37568
26-4231384
     
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
303A College Road East, Princeton, NJ 08540
(Address of Principal Executive Offices, and Zip Code)
(800) 208-3343
Registrant’s Telephone Number, Including Area Code

(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 ☐
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which
registered
Common Stock, par value $0.00033 per share
PDSB
The Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).
Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Yes ☐ No ☐

Item 8.01
Other Events.

On May 9, 2024, PDS Biotechnology Corporation issued a press release announcing it hosted a Key Opinion Leader event on May 8, 2024 during which prominent experts in head and neck squamous cell cancer (“HNSCC”) discussed positive, updated VERSATILE-002 data and the unmet need in HPV-positive HNSCC.

A copy of the press release is filed herewith as Exhibit 99.1 and incorporated by reference herein.

Item 9.01
Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
Number
  
Description
     
 
Press Release Dated May 9, 2024.
104
  
Cover Page Interactive Data File (embedded within the Inline XBRL Document)
 
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
PDS BIOTECHNOLOGY CORPORATION
   
Date: May 9, 2024
By:
/s/ Frank Bedu-Addo, Ph.D.
 
Name: Frank Bedu-Addo, Ph.D.
 
Title: President and Chief Executive Officer


EX-99.1 2 ef20028859_ex99-1.htm EXHIBIT 99.1
Exhibit 99.1


PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer

30 month median overall survival (OS); median OS independent of patient CPS score
ORR 34% (CPS≥1); 48% (CPS≥20)

Phase 3 registrational trial planned to initiate in 2024

PRINCETON, N.J., May 9, 2024 -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, hosted a Key Opinion Leader event on May 8, 2024 during which prominent experts in head and neck squamous cell cancer (“HNSCC”) discussed positive, updated VERSATILE-002 data and the unmet need in HPV16-positive HNSCC. A replay of the event can be found here.


 •
The VERSATILE-002 trial is evaluating Versamune® HPV + KEYTRUDA® (pembrolizumab) in patients with HPV16-positive HNSCC.

•
Median overall survival (“mOS”) is 30 months (n=53) in first line recurrent metastatic HNSCC; Published results for immune checkpoint inhibitors are 7-18 months.

•
The immune checkpoint inhibitor (ICI) naïve cohort (n=53) met its primary endpoint of best overall response (BOR).

o
BOR by investigator assessment is 34% (Combined Positive Score (CPS) ≥1; n=18/53); 48% (CPS≥20; n=10/21); Published results for ICIs are <20% (CPS>1) and <25% (CPS≥20).

o
Progression free survival (“PFS”) is 6.3 months (CPS≥1); 14.1 months (CPS≥20); Published results for immune checkpoint inhibitors 2-3 months.

o
VERSATILE-002 data to date indicate a durable response in first line recurrent and / or metastatic HNSCC patients with CPS≥1.

o
The combination of Versamune® HPV + pembrolizumab was well tolerated.

•
The Company announced an updated clinical strategy with a two-part registrational trial focused on the triple combination of Versamune® HPV + PDS01ADC + pembrolizumab as a first line treatment in HPV16-positive recurrent/metastatic HNSCC.

o
PDS01ADC is the Company’s novel, investigational tumor-targeting IL-12-fused antibody-drug conjugate (ADC), which has shown promise in a clinical trial of Versamune® HPV + PDS01ADC + an investigational ICI conducted by the National Cancer Institute.

o
Part one of the clinical trial will focus on dose optimization with a data readout based on safety and objective response rate.

o
The randomized second part of the trial will include an interim data readout with OS as its primary endpoint.

About PDS Biotechnology
PDS Biotechnology is a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines. The Company plans to initiate a pivotal clinical trial in 2024 to advance its lead program in advanced head and neck squamous cell cancers (HNSCC). PDS Biotech’s lead program is a proprietary dual-acting combination of IL-12 fused antibody drug conjugate (ADC) PDS01ADC and T-cell activator Versamune® HPV in regimen with a standard-of-care immune checkpoint inhibitor. We believe that proof-of-concept long-term data have shown positive survival results and tumor shrinkage with this combination and indicate favorable tolerability.

We believe that with a novel investigational “inside-outside” mechanism, the PDS01ADC and Versamune® HPV immunotherapy has shown compelling results with potential to successfully disrupt a tumor’s inside defenses, while also generating potent, targeted killer T-cells to attack the tumor from the outside. We believe that data from more than 350 patients, as well as ongoing clinical trials across multiple tumor types and standard treatment regimens, have validated the potential for both platforms and point to potential broad utility.

Our Infectimune® based vaccines have demonstrated the potential to induce not only robust and durable neutralizing antibody responses, but also powerful T-cell responses, including long-lasting memory T-cell responses in pre-clinical studies to date. For more information, please visit www.pdsbiotech.com.

Forward Looking Statements
This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials for PDS01ADC, PDS0101, PDS0203 and other Versamune® and Infectimune® based product candidates; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning PDS01ADC, PDS0101, PDS0203 and other Versamune® and Infectimune® based product candidates and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund its disclosed clinical trials, which assumes no material changes to the Company’s currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of the Company’s ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; the Company’s ability to continue as a going concern; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the other risks, uncertainties, and other factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.  

Versamune® and Infectimune® are registered trademarks of PDS Biotechnology Corporation.

Keytruda® is a registered trademark of Merck Sharp and Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, N.J., USA.

Investor Contact:
Mike Moyer
LifeSci Advisors
Phone +1 (617) 308-4306
Email: mmoyer@lifesciadvisors.com

Media Contact:
Gina Mangiaracina
6 Degrees
Phone +1 (917) 797-7904
Email: gmangiaracina@6degreespr.com


 EX-101.SCH 3 pdsb-20240509.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 pdsb-20240509_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 5 pdsb-20240509_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 image00001.jpg begin 644 image00001.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Document and Entity Information
May 09, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 09, 2024
Entity File Number 001-37568
Entity Registrant Name PDS BIOTECHNOLOGY CORPORATION
Entity Central Index Key 0001472091
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 26-4231384
Entity Address, Address Line One 303A College Road East
Entity Address, City or Town Princeton
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 08540
City Area Code 800
Local Phone Number 208-3343
Title of 12(b) Security Common Stock, par value $0.00033 per share
Trading Symbol PDSB
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 22 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://pdsbiotech.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:SecurityExchangeName - ef20028859_8k.htm 11 ef20028859_8k.htm pdsb-20240509.xsd pdsb-20240509_lab.xml pdsb-20240509_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ef20028859_8k.htm": { "nsprefix": "pdsb", "nsuri": "http://pdsbiotech.com/20240509", "dts": { "inline": { "local": [ "ef20028859_8k.htm" ] }, "schema": { "local": [ "pdsb-20240509.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "labelLink": { "local": [ "pdsb-20240509_lab.xml" ] }, "presentationLink": { "local": [ "pdsb-20240509_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 29, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://pdsbiotech.com/role/DocumentAndEntityInformation", "longName": "000100 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c20240509to20240509", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20028859_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240509to20240509", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20028859_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 17 0001140361-24-025256-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-24-025256-xbrl.zip M4$L#!!0 ( -:SN[/VR1Y;DQ-N.G9$= M2.ZOOR79#@Y)P$!X#$W/G(-ME:122?542=G[ZW04H2O&TS")]S]I3?438C%) M:!@/]C\=]CN]WJ>_'ORR-\P #$#CM#WU>13N-X99-FZW6M?7UTWQI9GP04M7 M5:,5QFF&8\(:!7P4QC_N !?%/D[GX-,E^&M#0FN>Y[5DZ1PT#5K!"-EOGR].;L"SU? WH*V,XS@-$C["&VHUF*ZBJ&5K8S294!QN/E018%"P.E[!:9RQZA8 &0)),XX[/5 MP$7A8H4)Y[!,U]4H2A>1R;B2S<8L74U,*&Z)8E%'5U2C.N:,KUT!7@M*2\ 8 MAR1=C9(L6L G#QZKA7BHW'P"T)[0X:I>(#'+,PB=K#7RO_FW_Y' M4=!)2%B<,HJRI(T^\P13'M(!DP#RWU%")B,69XAPAC, G*0@KBJ@Z/SB+ @C MAG2S:32UIJ7KYDWU3C*>\7 PS! @9R$%B6%4:RM*@WY"9RC-9A';;P0 JP1X%$:S M-OIT&8Y8BD[9-;I(1CC^M(MD>1K^'VLC31UGNTBTJ> H',1M%+$ OI D2G@; M_:K*?[O(Q^3'@ -W4*4L"N2_72#U'@VO4$CW&T?]\^-0,/?7D%(6-TJ$:)B. M(PS(Q$G,H,9>.&T+Q!G/'R6T? 2 4Z W#PF*\4A496'[$": BDDXCO"@(7LZ MQB3[#R;,-LS L3S=-#UF84,S;94%S#08L8V2:M/L0BQ 4JZ@++E92[G\V6^ MS&H'X911H%L$"N) _MEK+:"T'L-N# MKU@$4.8YZ,673;VQ6P90Q0@DUK<2&IC8HZ9N6L3$]V-Z -.@F8ZN>EIMK/H,I!/@U06&Q/& G4))!2G; M]0/+] G%)C8=IF%J^:KM40<[KFKK=@VD3@_[1X=_7T*HM3BI'*9$"$F6'NP) MG=I.I;:$9I'4L>TA%ST(AE?*MIO3E#:*8B$K]QMI.!I'#%:];+[:IGQ-DPF7 M;])F:!>HR]&N1+V 8W+FRK>0BO<@9!Q)'-E*)=;I?5N9:,V\B\73AD0JS*;J-GMWU#Z-5'J=SO_N.A=]KI]='AZA+J_=;X>GG[I MHL[9]^^]?K]W=OJB>.KK\/S78?]K[_3+Y=GI#CKJ@#ZV3.]%,5/788;V?-XJ M5E9]A K]NX)ME_J[#\$%?%8.=!5[2QQO6+SD2[W*EG>8$671*EHOBHO:3/JB MT^FNF\[CLXOO:*UN+NW*W+J;ZV3'L:P @UPF8!D8U/<\DU';,XE*F&9K5@V= M["K?EA7R@PDRGY>-+.TWN4QROOG+KYJM[A84>G5"@0R]Z)Y>HHON^=G%Y:NC MNB0Y()]#3/ M,%\=/V&@"60NV#CA&=HJWQD&$XVE&6)7PL7DLIC1[?;]M9Q'5T33=!<;J&6T-SGA_UT>?>V66W\_7T[.3LR[_!>+T .7QX*:W76TO\ M[2RPK>X4*( $07(I4Y((X13UQXP(IY2B,$:=(?B5C&^_.LHU^//AKN>;9+2% MX678CQBT&$5@1!.Q[]%0&_)]C"DMW_.>Y.-C(WK7()P" M3/E4(_(WI^H\IBE!82')6=@#/_\"74J/;V M..'46'209#7*2,+E[D,;P2I@7.Q-W"^">C%4&QH. M(<3!3N";AI!/.C%]YKJ!RP+-=!ZFBL66BH@+96S,DRN!D]#!1RS"UY@O1RKG M[%4AVX+G5OV>T3K3:;[/Z3P.(P9E/N.5N3,MB_IJH#NV%YB4>)YMFZ:M@R&E MV51.38V K:88CF6[+S$W;XS5[J;X)9[VBE@ID?.U1'Y*-=W#ADT\WS$=3?-< MW34PZ''?"'R"ZY!?MQ53-S3#739.E^A_#]E_D1_XP>N*P-)6>W%F?5C'SSSB MMS$73^:1U7:<5";"NSX#KYJCOX%3F](P=[O!L%M0/-OO0HZOID,G&8W"5*2) M("&=42X?'C_BMS_SO>9%L]]$W=$X2F8P]8OR$9TFS?M&?XLQY!]PZ:3%^:#M MBLT:^AM3TX>4.W."U\.W X]G_#*YCJM1WL#V+8\YV-*("8^^ M+?ZGJ@D.; !?ZOBJ/(P)RY)X"<&:B$E9<\;/P9@,9<;2'+N NBH.= -0,4S- M Q7LV8%#/ RDU6UW;&G'I.&9EDX15#9P'( M I;N(!Q3!.1!@CXOZL8_A)6WUDZV8(=#SO!M5PE8%XP[TU(-T_0UXE/B8F99 M5N#K6%?KY$>XZM+D;J]?="<)J(+S(;CRRZ:_24ULN8:!F69JEH7!]G=5+P G MP&&^[=>Q/44>FV$:;W6UW42(_O*KJVO.;HHN6<3&@AZ%LMT1UD8T$3$))"9, M+KA71_P/%-8M(S#6G]]$Y.E5A-IQPF'A%X%)CHK70M3MH# 0 N#3G10&_ MB=5* 0KR?5:4%>LK (LDN1:U1=PG%$9QBK96[/:+YS8*07V&!,:4,E:(&_2% MQ8R#.NG%T-4D=R<.FWHS']UV^Q$A2A+A-,T3_DY@ )>BTH:BE<\9DM3UIE4[ M'6)1^=T*&M1T/?+T@)6^QT822>XPF__%PPP6I_"E)G'A2*05/6?HOD,TICFN M[ILV4WV5V'J@$E]GH +]&CIW*3SI)TGD8UBO&?".\-\]QS1W[XN_U"1E+NI6 MDG)YR6S0L5L=XBJH"S2JD!>-*_OE%Q/@(U.W"L86W%[9IQ;;TUN:@SK'%T@W MU"8 ;L##^V#>=\*\_02D.*R4>/ =5!'HHZC"N2YS*0ZPYV"=FJ[#L$5,2@W5 MU3R,F5K#&?J9.?>&M& WY;1=YEO-Q(JF5UAW(:]DSKBFVLPA/WCW@W=+WCWG M3"A=D9PN,_R$@F$\=6,K3LV9IKN63K336J# M;FJ&=@J9=X'8V^6L0VFF%ND'F,7L,^WD[*I>$3%3\@#!(PSNC#X>3*N ME&I%, $&_!A?_KVD&SE-6U^WT5?@5(HN$: K/A5Q$WFVJ(K[)N3)!E(I+L6! MU3Q7F QS5?'8;5!][<;O'YWKKW\*ZF^U(&5$P,S]8,XAN&XX/O0+'F$=,UL:IKEJ-I)M%K[% ) M:P;603]+R(\=-,8<7>%HPM"?U":(8<- 8W$$=E@CLW!3PN<-S]SSYL05,BP7 M8959]E7'UBW-TOS -561^\9\S; P4]U PTZ=?_/4EFOOM9K>[# M"&-=":=*?O2]7>^0_<$E6&ZG.*7X=]3!8[%_@[YC_H-EY6[Q$],57\%^[<54 M6.P,^3-$Y-[:"$8$6H?)O+9;&U]ABH"&8.Z+3$]N3=EM2^R5B>O5'5I32?0B&8: M.@Y,V]8P5;!HN;4T/@0E9!"XG,&&<2 =TDC()!5@7&^#B.J(BGZ^.#\^QP/VF3/\0R0BS8,4)&*8BUR3;#AO-!^19/GBR_QRD47*K>MA MWOH8OBB^^*3@(!.DQ=$UGJ55LZ%"_[RWG-1J-?VG&A$IOJDW-'[HN;3JF&\3 M[:=)XG#TYXT#K\QEZF5LA-RFJOT!PZHK!Y0?,>B*@^=I3 M,94W\/VS>]$_O.R==!55U1%\P[(KH?TG\8AET&GN+'P]_Z=2-H-D/\T'&&$/ M6F9/7#4+=L*#3,6',6IS@]HB;$"E,/V>YO2>\IV'HPRKS MO*8FYRFYR6IAO-9CVIA<^NR+RB(S8 MA4SEPBU6\H:UY>:=CM6YV'1[:0 _X2:AHC6'V:AQ("S MO19^]"47[V<5U*+K@NI;3I,"N_NBL+N/I"E=<3(?:*&\C@1XV.+25/-CW3QY MW702P 2):"?J"<)B(GWC(^%#RYL6MAAH'D]^:,-2%SL/K\/ M?[-)=(^?@X^H\>:BQJ]R=2=T@;,)KW6V.%_:BY&.#<4UJC>=YKM?OT]"7GA_ M]?:$=U9MF]%)-$,$3^1O3(B-X?R23]&-SU *PX("$??+RGUIGPUQ%(C(2![1 MHN('IAP& -]*Q&3=^(C6B]^:=-F.A,D$''#_8;^9%6Q MDE?ON1_SF4R.=S$=F[7[-TF2)WNC^?7&;;1P'? C,\K>D*GT>=9^[##,E[YA MZZYQU+^UI96VT#$HKA_H,Z,3Y9#29 >=#YM'S7JW$[Z-]?Q'E;AYMG9[[0Q\ MD/X922\SK-M(N-7R5WQDO+\S#%FP= ?3?:'.YW9\GB.?Z">\C/EY?_1HKR5^ MCTW^/ELVB@[^'U!+ P04 " #6G*E8*6_(\3T4 "180 %0 &5F,C P M,C@X-3E?97@Y.2TQ+FAT;>U=:W/;.++]OE7['W"=VJQ=*\FB1+WL)+6.D^QD M)XE==F9NW8\@"4H8DP0'(*THO_YV-T"*>CEQUHF3C5U3D02">#2Z3Y]N@)PG MLR)-GOWU+XP]F0D>T3?X7L@B$<^>'-I/5_@_[39[(T.1&1&Q0AVQYUKQ2,MH M*M@KF?$LE#QAERHI"ZDRTV*OL[##[,WT]T*%92JR@H5:\ (:*8W,ILUFSB_. M8ID(UO,[_8[7&?1Z?N/^4Y4OM)S."N9-)@/69KUNSV_>WF[;J1RZN3P)5+1@ MP314B=)/]Q[%]+?'3+%(Q-.]6&5%.^:I3!9'[._O92H,>R?F[$*E//O[,:/K M1GX41\SKYL4Q*\2'HLT3.#75JLRB]OJEYL!M MD\D\/M?6]*^4F@JWJ??X],I\SH\.F>3/E4 MH.R\SA_Y%*[<8;_;%N-.!'7^XI(]EZH0X8S]_O+B\N3]ZS)S&0(5OI>HZV^%:(P[%S#;/6"718E6,O++,J5S*!<9F#6VA1@])E@%R(L MM8;A'KX5!3<%+V3(?CG_W1NVSY61A;P6[!9(P4^IK>0U"W#^[/#BN MKIY=@M@BD0OX!S! Q2P'0>'7T_-+9D*EQ7[!#[MN5N7[3(NI-(7FZ)-@M0I2_#SA649>#)8+=!>\$:H[^I.O MBS"59>P2B_4JGY 3.[B];O3E^_/WK78N\Z_.RWVEB_8I&4=(KCI!A)DX JF M"_"=.E=6"FS_'3<1__,(JST_8/NPVKU>][AQ$Y5XQTQI5LP$@6UB$S,1*I^CT9VJ.32^] M.]TNF%F80J2L +5 ; (P858I]AP*@P0ZUENLO[RY/3RNAX>A (B"2 M399PTXH_?N0-N\>.-N0.<%NLS"-B4JMP#V6\%E29I:* 84(M&+=%[+Q&;!Q; MAYV F8!-+%"2>(\5"LR#!0*6$"@%>U(^N]V(01&$&^^3P_)99\5(OLA@&A:W MUL1:<\M*!0^ 3N*JF)R#-DR?[G7WZ'?.HZCZ+:.G>Q\'_=CG0W\RF(SY>#P93N"VA!OS=._%Y?FK-X I[['M+R>3P^M[#(OK,YL -%D@EJE$7*K\]=*->@UT, MCS^K8TM(MW:\ T.WJE+=P;KBW:3-[\$J5HW,>A)IP%AX4@*R F#\#@C%$<>> MF#*OVEXGXQL3P+'3+("=B7;%\;V5.9@42 H3FS?[!?7_[? M^XO?7IQ\JU[WU[H38;!J/M@Z3^SI;_=Q?.=.T_/ M+FMG#M9?Q0>&[6=/!WTRAIC")K0K\*LN;(((81DVH?H?L_,R2*29@6/6PI0) M& ^PHXH(A3,@%A2)08L4 "MD/UJP4=L;NS[OS81"(4(QBGDO&@E_TNM.@F \ M&HGQ?GUT-B;1/XH&L3A,/YQ;63@?[\VHKY[ZP!=9<$"S.$:=%E..5H$Z($PAH)9 M]"F4F5%I(#%)4:?7+C%]1/F9 U8E;8Y9]M0;'X+9;,G>T,7N80]3.]N=#1BB M=2J/DP)NV,@P&8U& @ C'R!P./1\-N-_*&X9"/ MNWS@/YC4SVE2YUI-0:T-YG5B+<0F:SM_M<+:AIU^3=M64Z">W_&V7 *M_R+" MUFOW[YNK#7NC+A_VO$G4[_D>>-P)#T;]:!+'XU'H]_H/1O-S&LV6G&&A\!-S MX1&,![YP3(62JM5<:U=\@^[B$#/&ZX'.6FZ@86[W9A+Q@/MC,9YTXZ[PHS&' MOYC'HV$XB<6P&SSXD9_4)#!P"8EWV9T2"#BVIO3N/H6WDE%CJ,X['L#X<>>'\0Q'X]&D]%83'PO$#^N!3TD .[&CMQN(?B% M3)59B/MO6;U?%58'$6AK5DP7UC> !YJK=LYUL7W?MKF;"%U 89[O[CL M>B,%VR7;Z:\&SZSP.-/-M;;V)"K_>GANAO]WA# &P6]*/:ZPW'H^\-! M;S(,!A.O"P0S\$?1T/MQ$>#!A_Y'L5AE%Q!F%4L<0.CR1L>&9>I:)*U&^L,9 M>)DJW;;[_KB5]OI-V^NU8S)WGA42C_*U(UU.8:6S/\HILM-]Z.:@Y;;I9V!W M9J;FF=VPMTR5+Y'&(L@WPX=-!&@ !B#A^OQ?G[[&F45EB/@8+$AV[ZJK]A 5 M>YW!+459B'MCSGW!Q6 X[@?#<>Q'(R_P!^$D' \B,>[Z/>^!.?^L5H\^6X%S ML-C42PHP%3! M'WC,Y[H1CR)_N+^$Y,0;3*(X"">3B>_[?#P<@_/C?H_[PV':BUE]-A16K%)_5P*7"Y5N/U2Y MK8NZ^1Q*V@$6M7E I_Q2+M8?FV*^L> MLXHW]&YY8+\IA[73YSNY^XU'2ET'>AKL=UL,_SNXHU/G)P'JZ,:)TU6E_ :# M6SG_[DZ] @7]S\^HWO9HZE*3/O^,:HR"MI@MZ%6QK 4 M1((9S%49V)$4BUQ8 Z\ IY$W=)"$CS8@7@ D2)M7Q:$OI8N[TT@AT*$4Z-5L M@Q:D8/K+F@$^1,G*P@(!J\_MNX_O"Q=L3VKS=1,E'!W(C^BUM6@W4O!PLS#5YF^' MO<)-7%1N("R@-(2#+= ARU@D>*7;/PTRG\\[>60"RR8Z@ R[G@WY4@U["#9^ M@F #5'..4/A&J2O4\D2R '^152+. U14<_!-"+PZTG;B! MFGJ@;']IK^@-I=W+2@70""@"@GQ)40(0>^]EE2WX#0(!P!J:KL$*I09N*,Q2 MD5Y^0"("_.\DI&##F_1]\D4\Q8=1HQ8!4-WTZ.1333<:ZC<;.F!$736-]A,/ M&NY^>-!F\Y R@)T58!TV! * :4@JY8OJ>3DV58"'+4J09/1^ 6H!G\@+"^JM M(0M.8!:710D@1L%4"YUG%L$G/=H&GQ4A@1FJ7-@!&SR^$M>O,L"W/$"! M28B,-=@#84::Y[3@%NV?!HN6(>HV[ M51?@1_@UEXEC[:U&FYWEQ%_MUCI+C)!65>FFQD5B-AC+@&. &($2K*"7$#N@ M!,EST3/-K,PQAM,@O1A6;BED*U6\4@O-5'.QOEL@KD=0#6TK7779T<*-G M\+KIMAZT^F/+D$B1-X8/ZRY"\-_KY=,2"!Y8G2MN5>5 4W&MJ]I+HS(2@(QK M-!!W,!(-6"' X'73N4E74!-VZCCVT=3<6G=,2D-<> "&.+;H(9!4@V([\HZ; M"PZ'[3.O-L>S8[9DB*YI[/^::\K0Q#S$ YP-=M4BN,9D5P+"M:!SM-7>74!- M%%LC.-KG&7#)@6+29!K$3B/^0&UZ9X8YWMYBK< 1"WF.3[G#F/\LI;9+UB2! MG[[?S)@N,^ B]4/"Z_6K16_B*T8=($+L@M+0E*3"$*/" !@.3,/A9S;=,97J M[0A D3$O$5FT:$JD;L$"#(((8LL2I7'4&%LF$-9M/ SN+J9"(XA7&TR8?J/< MN<(=5DQU110R.93"1JS2DCIK+NG5-!:NZB'6HD?'!"H#T1SJ^Y9)KKH4MU+- MFF0E8%$97,'EH+5?"8>W-5O[630F:'AS.MME3@J+YIQ7P3%0EP*C \<^=JT_ MG5?!QV[P53V (]5F>\JO,)(HR IEB+8#$W)/PHJM3<)8#2J3:6V]7/5 >E6] M>("06,Z4BIQK78IG_?YEYH!)U S4A7KI:1U7>K!RPAU($$;LNJO6!@]UH[)P M7628$&UF8BG<_=+K]AOH_-53E]C5-PN.G18V$KYK MZN@ PBU1O2!6:K;*C;KE B GO_B]G@M?>PJHW%W.DM:-<2>,;JBC63U#'FGL$EU&M_PRI1T7PF+(_! MRG5+I$0(./1*'3!+&&^.3PYNU[(=,'2SLKK[6Q4XV &:8E>#.W-\6;3J=K> MQ4W0N\U5+=6WP=:6;KD!:;3=1)!EDS<\)!P7F0995WYR98L&O6EC]=PH]S_! M*Y9,Q^9L:W>-<5NBS.;$*Q="'%+@>;":PS$;PA+@WB :Z,:1:F$C0$QK';10 M >QH(#1*%I0:0_);(0F,MD#C!M:([,.N$*9SEV+0 K6I8HTP.TSRA87E",#, MAGI_HV:!,'(S2W4DB7DF8\>PLM/::QN,J-C:9&+$#;N[BBL+* =)B,=@JV!2'J M[1 :" \;>T_K$-$4 (7R7,/T-F1"I!Z[KZ_L!/N=D+Z#4R]U%\,%F95B[>RN M$YGU!\WH:C,X8 F>5TZX?2T/F&29X"8E!/2Y@EZ6LX365"K#YBP,+7(C%[2A M]S \L%N[28PAHAV8%M=2S$D?4]1;0)MJ9);&VD IY"5$1-S&4"Y0QUROC9]( MOBLTWT;;JS%:0"$56$.)F[8&;IA!JZ2%M$5!MV M/+."UD-;N5FX/-RU+=O@ M<@.X*ZV%M(HB$B/F^'L]I+&2)Y+>6@TK6YLK ^(UH98!OF02U;:*ER_@=O;* MK=Y:C/VVSJC4@G]ADT].B9[F"_=:Y[#1STHUTF:>7*9?)4>T*MFW@WZ*3O6=IBDKQSP26 MR #]<2NTMK/_8]L?O0KL/HWO7\ M&?#2*0 ?/HG [V$,0_9"3+40]VM\$S2^ MT634'DVZ_H/Q3=.&4OQS&-D5RO57-[^[N^]39V!N?@/^;<^XW-T;\+>?CVE\ MNYF8V\JT0G_]RY-#//A%7]S_B.'_ 5!+ P04 " #6G*E8Q"'-DM5=;;],P%'Y'XC^8O#N7ID6T6C>! MMJ%)@Z$!$F_(=4Y;B]0.MDO;?X_MU&EZ7=/ F^-SOHOMC/9 :J(!2&P53K8A!%1:9& M3&B@TY"*6=2).]VX%_>-HQQFP/6]D+-;&)-YKH?![SG)V9A!%B"S!*X&2U41 M+1:+<)&&0DX,29Q$/SX]?G72/MR5P.&1!0@-3.KWI10 M],^6E9-1TV49".3_=SV6YYM9 ;*#[\\/QWK0^;D5=&[;_CW/[KAF>O5@SEW. MW+8'B&7#X&1&)>W%,Q@SSEPYQ>96B&.$D6>H#PG/4$F':GQ7T2[)+O]<0?;$ MK]UXMT36Z'7**20E.9WG%P WSH[CUK/^&'Q;13M]54YL=Y_M/5-U0FK$]V[N M>NM/""G6G5_>]X^".IHR6_D;Z2 F@EPK/V.K.0V7*O.%=-+#D6ONI(?==#MH MH4K%G&NY:J)0,H MARVT%:--E'VZ'313W;V]^^5MR6%B'V:'Y7=AN91;*&QY<-+!R=OV/G1C#_H2 M_>WMU(5LM/T^WXW:'4#]H7;.PAW$?F&/L\M/[?+3Y&(7W4C:G^PS#;AL*]O% M\3N_1>::J!UCAWMF2Q]Z5+7Y='$W;MEN_BXP_JC$LBYQPHH5@@ #!6 5 <&1S8BTR,#(T M,#4P.5]L86(N>&ULS9QM;]LV$,??#]AWX+PW&U#;M=P-2-"XR+*D")8F09)B M3Q@&66(<8;(84'+C?/N1DFB;U)%B2C'6F\;B_7E'WOTHR72E]Q_6RQ1]P31/ M2'8TF(S>#A#.(A(GV>)HL,J'81XER>##[-MOWG\W''[$&:9A@6,T?T:_4!+& M-(D7&%W?7-TG*4;!N]%T-!G]% 3O=LS#(>^>)ME_A_R?>9ACQ,)F^>$Z3XX& M#T7Q>#@>/ST]C9ZF(T(7X^#MV\GXCT\7M]$#7H;#),N+,(OP #']85XV7I H M+,HQ[W1?SVDJ'$S'FUA:!3\:"MF0-PTGP7 Z&:WS>% /D9LM@@CYNJ&OYS0Y M.#@8E]:-E#E*#*XWTV;90ZC*'R4IOL'WB/_]?'.N[7TPYHIQAHN+<(Y3%K+L M7CP_XJ-!GBP?4RS:'BB^A_VDE&[<\.P<\.Q,?N;9^7[K>>PRO 6'Z8X48=K- M.$M_S;$VPK@/^K*KU)J&?-EEEMDBQZ^0Y9TP[H.^QC0A\6D6^Q^X&JJKP=\6 M(7T%5)K!W"?@?]3 4%/>=,$^27'QNL!9C&,1F?LVG#O+T.7)MO2\\4TBR6O* MKR*$-J>3,Z^EQQQ'HP7Y,HYQPCP'4_YAR#^4LV '_YX0=OD\GN<%#:-">"HG M<30 ;452\+$KMK$\4-Y?&BK%.5G1""L1M".P2I!4WVI8D,-ERL+Q&P*<#3_? M#E 20[I9>8C^%@W_O!]O1]JTJ6 MNMP30\KJ#)2^#I$D005!0+^Q=[I^)=%JB;/BCGE42@^9ZBG()@>TH!@N9"G^ M=&!)LIDX0OQPOU"!.2?Z7,E([2H$4<92>0#J=YH4[%1Z0I;+5994-]&Y4GFC MIIZ21N/ FC&J"W0ZQSKZ8/VL;D9R^WYY-%>*6"16)A24"E3M2NZ!V5N2)E%2 ML.^DG]A- TW"5,%'+ZBG!PD<4-7'<^$4]*J#%!#/MFU(-.X73T-=2%LF93"; M.D&E16D]('E-,5\'F$V]/'OSFU-Z=7^/J8)+N[">J$GH@&I[?!=DC=YUZ!HZ MS9AM&.T8465%I7F_,%M4DMCF7(9;KQ>0OP ._["?Y_D*4VODM7(8?$#>'?[: ML72X"* 8EDNAV;6Y("I-?]>%OMSPZFC# UXCC5Z:E=).DX?U: /1C%A7'5H0YH63?;'")^O%].X7U8C8+I)L\9&2I^+AA"P?PPR^.3-SKUYL<"]Q"(15E2946WOP[HPUY-8)QY:!V 'F7\[2+QQ?QS'C+>\ M_G.19'@"4F_028>=FVF'^@C6Z\8WX@/B9G25]>(J8*HCL4PY M1#H@ESFW >,5*0\L*0\L*0^\4![XI#SX"LJ#%LKOGD@_*0]L*5<+WD)YT$9Y M$XQ7I'QJ2?G4DO*I%\JG/BF??@7ETS;*69%Z>C:?VG*NEKR%\VD;YTTT?'-^ MPCY>T3ORE)DH;ZH@QG=571'>C-P9WY)K*[IW>C38YC;^C95;>T0U4#F(:6V! M(:*W8I!G P:^:2Z_^E[1:TJ^)%D#+ALIQ'5#VA7+]E%YM_1C/Y[($/)D+26=G1DD\N; H 83B\*D/UIWQ.P*YN5M\;\L C2Q7(A#/"IHZPAG94MJ&SJQ2_NVF(0S,;1BC+B)\'\C@]2H4)GKB?4-+L\DZV)Y?1$=M.G]GEL53HK M_R!RCR;!#_,?D1#L^8EL746(.8LR@JIJ\RQV6T$]('A)[FC(WU=W^[R?D_7 MT0,K 8>U#!)E,NP+.G@4@S%[.)RK/AMNR1+\IEH1:*Y!P]J&(M$VI,*7YUW ME>H5&JKU;@XNV"?^UM:Z*:G>R?-'[S=&4<1(M,3>Y/YN06+L!6>=?J?7^1 $9T?A=EL,CTGZW[EXF:,, M>WS:-#O?96386N7Y^MSWM]MM9]OO4+;T@VZWY__U[68:KG""VB3-T&[W^OLLJ@E*8IP@TD4 M?%?!RYIZ@\' +Z('*$]$'*D/9?/5\[S]^C$:XWN\\,3['_=CZ^B!+Q!^BO,; M-,)?C-,*1FDYP M?7X=Q:QJWIB&I:EB<1ZDK"I(QJ2 M\@N T3S+&0ISE2D6R@Q;QAAG* K28OZ;$U7+-.,9-9ZFD*19#I59'LLX8F7& MB(4J$_]8TK!ZLI8(?XT8S]<.5R0^R+]@-+&M)'52/Z9W[I4R>#GURB,IBS ; MMKKB&HX/7&#&Y [FX%V0CH_WPK<4<,391H+Q=8R6FH+&F%P'+09/0Q?Y&A&U MH5+%'F 5E>T.9\PO_%!NV1^-&&W'U##PU&U23,-=54LAU0[>@=K7) M1_#=& M[)IOR2QZ6U":XA447,W=!354O9)$ZMY_-[KO?5NOO %GU+Z$@ZZ^O:B3]"^E MD0XX ^R _:7H-8GQ[2:98Z8);PO+I:F&X\]O1W>_XT:BT!5.2NH*! MJK6[F$9B5U)(M7\!K_8X#2E;4U;4-^5EXDNZX<4\7M+(O)L*:2KAB M=\4HBGBAF7R[(2GN&1WAP)7<8,1!=4)]48U<8$RC^CN0VW0V^D%#"P0-+1"\ M)POH13W3 L&3!2#W^&ST^PTMT&]H@?Y[LH!>U#,MT'^R .3&7XG^)?]XQV9T MF[H,4$69Y#]& 1??6M ITA\G4<)#[OR5R!=7MG=LPN@#V3^#8U7? C59H (% M[@-W::>8H9)).0)^)U#9>7^;XSP.E"'&@X"" %?>7,I)N[_*H)2&WQZ4S"U=9ISA RZ-\ +E[*,Y9(X:107E32#T14@K!4]=! MO4;/\DBE(.2.H'A"-IZL:&K^]<86ELM1#<-3LZ:$&D6KHY6JD'MV4QQN&/=B M+YC/1)F:JK:P7))J&)ZJ-274J%H=K52%W'.;,22>N)\^)G,::Y(:8W(QM!@\ M,5WD:Y34AJHG92#WS6YIB;3A(3<'0JZ*$0%/V/I":N0U)E B0^Z,J2/,U2Y< MH72)#3^@NR#:D;@,@:=S@U(:'I'+&932\!M@5PEF2^[3KXQN\]4E3=8H-=_\ M.I&ENR$+$I[\S0MK=#]D2:3, +DI]B?W<(Y3SCG9I/)7/?U1."=&KI,% T_Z M)L74B&Y)H>2&W/&:TIB$).=>_89RS C2+\OL '6$-P#@J5Q;1MW1W3!>Z0NY MSS5A6-@2IR$N_D$A_J_#[A:+RGUR/5 NE L(3_?&9=7H[\JC? "YSZ7Q'V?9 M!K/&;K#"S9XPP,$[HZ[$T_QAR*9<\M)>VH5?6<(;OD'\]7P?$2_BK]J?_@=0 M2P$"% ,4 " #6G*E8[S%^$O81 #Z<@ $0 @ $ M968R,# R.#@U.5\X:RYH=&U02P$"% ,4 " #6G*E8*6_(\3T4 "180 M%0 @ $E$@ 968R,# R.#@U.5]E>#DY+3$N:'1M4$L! A0# M% @ UIRI6,0G(N1% P /P\ !$ ( !E28 '!D'-D4$L! A0#% @ UIRI6 ?PY8IZ" ,%8 !4 M ( !"2H '!D XML 19 ef20028859_8k_htm.xml IDEA: XBRL DOCUMENT 0001472091 2024-05-09 2024-05-09 false 0001472091 NASDAQ 8-K 2024-05-09 PDS BIOTECHNOLOGY CORPORATION DE 001-37568 26-4231384 303A College Road East Princeton NJ 08540 800 208-3343 false false false false Common Stock, par value $0.00033 per share PDSB false